Abbott Laboratories (ABT) latest performance of -0.40% is not what was on cards

Abbott Laboratories (NYSE: ABT) flaunted slowness of -0.40% at $116.54, before settling in for the price of $117.01 at the close. Taking a more long-term approach, ABT posted a 52-week range of $91.64-$121.64.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 6.10%. Meanwhile, its Annual Earning per share during the time was 19.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.29%. This publicly-traded company’s shares outstanding now amounts to $1.73 billion, simultaneously with a float of $1.73 billion. The organization now has a market capitalization sitting at $202.77 billion. At the time of writing, stock’s 50-day Moving Average stood at $114.52, while the 200-day Moving Average is $110.54.

Abbott Laboratories (ABT) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Abbott Laboratories industry. Abbott Laboratories’s current insider ownership accounts for 0.66%, in contrast to 77.05% institutional ownership. According to the most recent insider trade that took place on Oct 21 ’24, this organization’s EXECUTIVE VICE PRESIDENT sold 157,421 shares at the rate of 117.04, making the entire transaction reach 18,424,298 in total value, affecting insider ownership by 184,806.

Abbott Laboratories (ABT) Earnings and Revenue Records

Abbott Laboratories’s EPS increase for this current 12-month fiscal period is 5.29% and is forecasted to reach 5.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.50% through the next 5 years, which can be compared against the 19.65% growth it accomplished over the previous five years trading on the market.

Abbott Laboratories (NYSE: ABT) Trading Performance Indicators

Let’s observe the current performance indicators for Abbott Laboratories (ABT). It’s Quick Ratio in the last reported quarter now stands at 1.18. The Stock has managed to achieve an average true range (ATR) of 1.80. Alongside those numbers, its PE Ratio stands at $35.41, and its Beta score is 0.72. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.92. Similarly, its price to free cash flow for trailing twelve months is now 35.86.

In the same vein, ABT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.29, a figure that is expected to reach 1.34 in the next quarter, and analysts are predicting that it will be 5.16 at the market close of one year from today.

Technical Analysis of Abbott Laboratories (ABT)

Now, what If we examine the latest scores posted by [Abbott Laboratories, ABT]. During the last 5-days, its volume was lower the volume of 5.72 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 21.00% While, its Average True Range was 1.80.

Raw Stochastic average of Abbott Laboratories (ABT) in the period of the previous 100 days is set at 83.57%, which indicates a major rise in contrast to 58.88% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 15.64% that was lower than 19.39% volatility it exhibited in the past 100-days period.